EUVIMEDEUVIMED entdecken
Open Access

Oligo-CALL: A next-generation barcoding platform for studying resistance to targeted therapy

Yingzhuo Liu iD, Yi Ban iD, Dingcheng Gao iD

Science Advances · 2025

DOI: 10.1126/sciadv.adw9990 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Yingzhuo Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, Weill Cornell Medicine, 1300 York Avenue, New York, NY 10065, USA. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Lung Neoplasms. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Understanding therapy resistance requires deconvolving heterogeneous cell populations and tracking clonal trajectories. While CRISPR-based cellular barcoding is powerful for lineage tracing, many platforms suffer from low efficiency and limited compatibility with single-cell transcriptomics. We developed Oligo-CALL (Oligonucleotide-inducible CRISPR transcriptional activator–Assisted Lineage Labeling), an advanced barcoding system enabling precise lineage tracing, live clone isolation, and seamless integration with single-cell RNA sequencing. Applied to lung cancer cells treated with a KRAS G12C inhibitor, Oligo-CALL identified clones consistently enriched posttreatment, supporting a model of predestined resistance. Oligo-CALL achieved >95% efficiency in linking lineage identity to transcriptomes, uncovering diverse clone-specific pathways with underlying resistance. Paired analysis of barcode-matched clones from naïve and resistant populations revealed transient and fixed resistance phenotypes. Notably, DNA repair pathways are recurrently altered in resistant clones, and inhibition of poly(adenosine 5′-diphosphate–ribose) polymerase synergizes with KRAS G12C inhibition to overcome resistance. Together, Oligo-CALL provides a versatile platform for dissecting lineage evolution and molecular dynamics of targeted therapy resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmLung NeoplasmsHumansCell Line, TumorCRISPR-Cas SystemsSingle-Cell AnalysisMolecular Targeted TherapyProto-Oncogene Proteins p21(ras)

Substanzen

Proto-Oncogene Proteins p21(ras)

Autor:innen und Institutionen

  • Department of Cardiothoracic Surgery, Weill Cornell Medicine, 1300 York Avenue, New York, NY 10065, USA.
  • Department of Cell and Developmental Biology, Weill Cornell Medicine, 1300 York Avenue, New York, NY 10065, USA.
  • Neuberger Berman Lung Cancer Center, Weill Cornell Medicine, 1300 York Avenue, New York, NY 10065, USA.
  • Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, 1300 York Avenue, New York, NY 10065, USA.
  • Department of Medicine, New York University Grossman School of Medicine, 522 First Avenue, New York, NY 10016, USA.
  • Perlmutter Cancer Center, New York University Grossman School of Medicine, 522 First Avenue, New York, NY 10016, USA.

ORCID-Profile: Yingzhuo Liu, Yi Ban, Dingcheng Gao

Förderung

  • NCI NIH HHS

Zitieren

APA

Liu, Y., Ban, Y., & Gao, D. (2025). Oligo-CALL: A next-generation barcoding platform for studying resistance to targeted therapy. Science Advances. https://doi.org/10.1126/sciadv.adw9990

Vancouver

Liu Y, Ban Y, Gao D. Oligo-CALL: A next-generation barcoding platform for studying resistance to targeted therapy. Science Advances. 2025. doi:10.1126/sciadv.adw9990

BibTeX
@article{Liu2025,
  author = {Liu, Yingzhuo and Ban, Yi and Gao, Dingcheng},
  title = {Oligo-CALL: A next-generation barcoding platform for studying resistance to targeted therapy},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.adw9990}
}
Kostenlos starten →